BioSpace News Archive

Laurent Pharmaceuticals Inc. (the “Company”), a clinical-stage biopharmaceutical company developing LAU-7b (oral fenretinide) as a first-in-class inflammation-controlling drug candidate for Cystic Fibrosis (CF), announces the presentation of results from its placebo-controlled Phase 2 APPLAUD 24-week clinical study in adults with CF at the North American Cystic Fibrosis Conference (NACFC) currently held in Philadelphia, United States.

Axcella Therapeutics (Nasdaq: AXLA) today announced that it will present data on clinical plasma proteomic biomarkers in patients with NASH at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting being held in Washington, D.C., November 4-8, 2022.

AI Proteins, the biotechnology company using artificial intelligence to design synthetic proteins de novo, announced its public launch and the close of an oversubscribed $18.2 million seed series co-led by Cobro Ventures and Lightchain Capital.

Incyte will present data from its oncology portfolio at the upcoming 64th American Society of Hematology Annual Meeting, held December 10-13, 2022, in New Orleans and virtually.

CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has launched its new Barostim NEO2™ IPG.

Isofol Medical AB, announced that the members of the nomination committee for the Annual General Meeting 2023 have been appointed in accordance with the principles for appointing nomination committees that were adopted at the Annual General Meeting on May 19, 2022.

Today, Health Canada authorized an adapted version of the Moderna Spikevax COVID-19 vaccine that targets the Omicron BA.4/BA.5 subvariants.

AtaCor Medical, Inc. has announced completion of its second human clinical study of the Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Lead System.

Microbion Corporation today announced that the company will present a poster at the North American Cystic Fibrosis Conference, November 3 – 5, in Philadelphia, PA highlighting the activity of pravibismane against bacterial pathogens associated with lung infection in people with cystic fibrosis (CF).

Endologix LLC announced the five-year results from the LEOPARD randomized controlled trial.